 | Parts of this article (those related to weighing public health concerns with Janssen vaccine's crucial role in health equity and mitigating spread of SARS-CoV-2 spread and resulting mutations) need to be updated. (April 2021) |
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1953 |
| Founder | Paul Janssen |
| Headquarters | Turnhoutseweg 30, , |
Area served | Worldwide |
Key people | Jennifer Taubert |
Number of employees | 45.000 |
| Parent | Johnson & Johnson |
| Website | janssen.com |
Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.
In 1961, Janssen Pharmaceuticals was purchased by New Jersey–based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.